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Abstract. Aim: To report clinical outcomes of a consecutive
series of patients with early-stage (T1-T1N0) anal cancer
treated with intensity-modulated radiotherapy (IMRT) and a
simultaneous integrated boost (SIB) approach similarly to the
RTOG 05-29 trial. Patients and Methods: A cohort of 43
patients underwent SIB-IMRT employing a schedule
consisting of 50.4 Gy/28 fractions to the gross tumor volume
and 42 Gy/28 fractions to the elective nodal volumes for
cT1N0 cases, and 54 Gy/30 fractions and 45 Gy/30 fractions
to the same volumes for cT2N0 cases. Chemotherapy was
administered concurrently following Nigro’s regimen. The
primary endpoint was colostomy-free survival (CFS).
Secondary endpoints were locoregional control (LRC),
disease-free (DFS), cancer-specific (CSS) and overall (OS)
survival. Results: Median follow-up was 39.7 months. The
actuarial 3-year CFS was 79.4% [95% confidence interval
(CI)=61.4-89.7%]. Actuarial 3-year OS and CSS were 90.8%
(95% CI=74.1-96.9%) and 93.8% (95% CI=77.3-98.4%),
while DFS was 75.5% (95% CI=56.4-87.1%). Actuarial 3-
year LRC was 86.1% (95% CI=69.6-94%). On multivariate
analysis, tumor size >3 cm showed a trend towards
significance in predicting CFS [hazard ratio (HR)=8.6, 95%
CI=84.7-88.1%; p=0.069]. Maximum detected adverse events
included: skin (G3): 18%; gastrointestinal tract (G2): 67%;
genitourinary tract (G3): 3%; genitalia (G2): 30%; anemia
(G2): 7%; leukopenia (G3): 26%, leukopenia (G4):7%;
neutropenia (G3): 15%; neutropenia (G4): 12%;
thrombocytopenia (G3): 9%. Conclusion: Our clinical results
support the use of SIB-IMRT in the combined modality
treatment of patients with anal cancer.
Anal cancer is considered a rare malignancy, accounting for
6% of cancer of the ano-rectal region and 6% of all
gastrointestinal tumors (1). Concurrent radiochemotherapy
(CRT) represents a standard treatment option in this setting,
and can provide high-rates of locoregional control (LRC) and
colostomy-free survival (CFS) (2, 3). Combination therapy is
well-established for locally advanced disease, either for T3-
T4 tumors or those with nodal involvement, while in early-
stage cancer, exclusive radiation is also considered a suitable
solution, even if recent data seem to favor CRT (2-7).
Intensity-modulated radiotherapy (IMRT) can be performed
with a simultaneous integrated boost (SIB) approach, which
allows delivery of different daily doses to different target
volumes during the same treatment fractions (8, 9). This
strategy has also been used to investigate patients with anal
cancer (10). In particular, the Radiation Therapy Oncology
Group (RTOG) 05-29 phase II trial was designed to
investigate the potential of dose-painted IMRT in reducing by
at least 15% the grade 2 or more gastrointestinal (GI) and
genitourinary (GU) acute toxicity rates compared to the 5-
fluorouracil (5-FU)–mytomicin C (MMC) arm of the RTOG
98-11 trial, where radiation was mainly delivered with non-
conformal techniques (11, 12). Being designed for study of
the toxicity profile, RTOG 05-29 has not yet reported on LRC
and survival. Hence, we decided to retrospectively analyze
outcomes of a consecutive series of patients with early-stage
node-negative anal cancer who were treated at our Institution
with IMRT and SIB similarly to the RTOG 05-29 protocol.
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Patients and Methods
Eligibility criteria and baseline evaluation. All patients analyzed in
the present study were diagnosed with anal cancer of squamous
histology and were treated with definitive radiotherapy (RT) at the
Department of Radiation Oncology of the University of Turin, Italy.
Disease was staged according to the 2002 American Joint
Committee on Cancer classification and the focus was directed
towards early-stage disease including cT1-T2 N0M0 cases (13).
Written informed consent was obtained for all patients. Patients
underwent clinical evaluation by the Gastrointestinal Tumor Board
of our Institution, including past clinical history, digital rectal
examination and anoscopy, complete blood count, thoracic and
abdominal computed tomography (CT), pelvic magnetic resonance
and fluorodeoxyglugose positron-emission tomography or inguinal
sentinel lymph node biopsy.
Radiotherapy. Patients underwent a 3-mm slice thickness planning
CT scan in supine position with both an indexed shaped knee rest
and ankle support (CIVCO Medical Solutions, Kalona, IA, USA).
The gross tumor volume (GTV) included all primary and nodal
macroscopic disease and was expanded with 2 and 1 cm margins,
respectively, to obtain subsequent clinical target volumes (CTVs)
and then modified to spare bones and soft tissues. The prophylactic
CTV included the mesorectal region and regional groin areas. Nodal
regions were outlined with a 1 cm isotropic margin around regional
vessels and then corrected to exclude bones and muscles. A 10-mm
isotropic margin was added for the corresponding planning target
volume (PTV). Dose prescription for target volumes was taken from
Kachnic et al. (11) and was based on an SIB approach. Patients with
cT1 or T2 ≤3 cm disease were prescribed 50.4 Gy/28 fractions to
the gross tumor PTV and 42 Gy/28 fractions to the elective nodal
PTV. Patients staged with disease of cT2 >3 cm were given 54
Gy/30 fractions to the macroscopic anal PTV, while elective nodal
PTV was prescribed 45 Gy/30 fractions. Objectives for target
volumes were set so that for PTV, V95 would be at least 95%, V110
≤10% and ≤2% should receive <95% of prescribed dose. Dose
constraints for organs at-risk were inspired by Kachnic et al. (14).
In order to compute VMAT, Elekta Monaco (Elekta, Crawley,
Surrey, UK) was used as treatment planning system (version 3.2)
employing a 360˚ single-arc or the dual-arc approach after system
upgrade. For step-and-shoot IMRT, plans were generated with up to
seven modulated fields, employing 6 MV photons, according to
patient's anatomy. Radiotherapy was performed under daily cone-
beam CT image guidance.
Chemotherapy. All patients received concurrent chemotherapy
consisting of 5-FU (1000 mg/m2/day) given as continuous infusion
over 96 hours (days 1-5 and 29-33) associated with MMC (10 mg/m2)
given as bolus (days 1 and 29). A total of two concurrent cycles were
planned at baseline for each patient. 
Clinical assessment. Acute toxicity was scored according to the
Common Toxicity Criteria for Adverse Events scale v3.0, evaluating
GU, GI, hematological, dermatological, genital and osseous events.
The worst toxicity for each category was considered. Follow-up
included digital rectal examination and anoscopy at 4, 8, 12 and 26
weeks. Magnetic resonance imaging was performed at 12 weeks and
an anal canal bioptic sampling was carried out at 26 weeks. If no
residual disease was found on pathological examination, patients were
classified as complete responders. Salvage abdomino-perineal
resection was offered for persistent disease (pathology) or for locally
progressive or recurrent disease (imaging and pathology). Conservative
salvage treatment strategies were also considered when appropriate.
Statistical analysis. Disease recurrence was defined as local when
occurring in the anal canal or anal margin or mesorectum. Regional
relapse comprised disease at draining nodes, while systemic
recurrence included distant metastasis. For LRC, we took into
account local and regional failures. For cancer-specific survival
(CSS), we considered death due to disease. Overall survival (OS)
was considered up to death from any cause. Disease-free survival
(DFS) included all failures and cancer-related deaths. CFS took into
account death from any cause or definitive colostomy. The
Kaplan–Meier method was used to calculate survival curves and
actuarial rates of relapse. The Wilcoxon signed-rank test was used to
perform univariate analysis. Multivariate analysis was performed
using stepwise Cox proportional hazard regression models were used
to explore potential correlations between clinical prognostic factors
and CFS. Covariates included in the analysis were sex, age overall
treatment time (OTT), time between biopsy and radiotherapy start,
tumor dimension and grading. Stata Statistical Software, version 13.1
(Stata Corporation, TX, USA) was employed for analysis.
Results
A total of 43 patients were treated between July 2007 and June
2015. Patients characteristics are detailed in Table I. Patients
had a mean age of 58 (range=45-82) years and were mainly
female (68%), HIV-negative (88%), with an anal canal
primary tumor (84%), of T2 stage (88%) sized 2.1-4 cm
(71%) and G2 (72%).
Patients were mainly treated with the VMAT technique
(51%). Most patients received 50.4 Gy/28 fractions to the
primary tumor PTV and 42 Gy/28 fractions to the
prophylactic nodal PTV (60%). The mean time from biopsy
to start of IMRT was 92 days. The mean OTT was 42 days.
Patients with breaks of 3 days or more comprised 5% of the
population. Details can be seen in Table II.
Toxicity profile. The acute toxicity profile is shown in Table
III. The majority of patients experienced grade 2 or more
skin toxicity. Moist desquamation (skin), diarrhea with more
than seven stools per day and cystitis interfering with
activities of daily living were considered as grade 3 events. A
total of four out of 43 patients (9%) underwent a single cycle
of concurrent 5-FU and MMC due to toxicity. 
Clinical outcomes. The median follow-up time was 39.7
(range=7-102) months. Overall, seven treatment failures were
observed. A total of five patients experienced exclusive local
relapse after CRT. All of them had T2 stage tumor between 3
and 4 cm. One patient showed systemic spread (lung) and
another synchronous pelvic nodal and distant (lung)
metastases. All patients with local failure were salvaged with
abdomino-perineal resection and definitive colostomy. Among
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them, one patient underwent interstitial brachytherapy as first
salvage option and subsequent salvage surgery because of
persistent disease. All patients with metastases received
chemotherapy as part of their salvage treatment. 
Overall, four patients died. Two events were cancer-
related, while the other two were due to other causes.
Actuarial 3-year LRC was 86.1% (95% CI=69.6-94%)
(Figure 1A). Actuarial 3-year OS and CSS were 90.8% (95%
CI=74.1-96.9%) and 93.8% (95% CI=77.3-98.4%),
respectively (Figure 1B and C). Actuarial 3-year DFS was
75.5% (95% CI=56.4-87.1%) (Figure 1D). The actuarial
probability of being alive at 3 years without a colostomy
(CFS) was 79.4% (95% CI=61.4-89.7%) (Figure 2). On
multivariate analysis, tumor size greater than 3 cm exhibited
a trend towards significance in predicting poorer CFS
(HR=8.6, 95% CI=84.7-88.1%; p=0.069).
Discussion
CRT is considered a standard of care in patients with anal
cancer (2). Recent multidisciplinary guidelines indicate this
approach as a current treatment option in all settings except
T1 tumors of the anal margin (15). Nevertheless, the use of
combination therapy is largely established for locally
advanced disease (T3-T4, N+), while the addition of
chemotherapy remains debatable for early-stage disease (T1-
T2) (6). The randomized phase III trials that provided
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Table I. Patient and tumor characteristics.
Variable N (%)
Age, years
Mean 58
Range 45-82
Gender
Female 29 (68)
Male 13 (32)
HIV status
Positive 5 (12)
Negative 38 (88)
Primary tumor site
Anal canal 36 (84)
Anal margin 7 (16)
T-Stage
T1 5 (12)
T2 38 (88)
Tumor size, cm
0.1-1 2 (4)
1.1-2 3 (7)
2.1-3 17 (39)
3.1-4 13 (32)
4.1-5 8 (18)
Grading
1 4 (9)
2 31 (72)
3 8 (19)
Prophylactic colostomy
Yes 0 (0)
No 43 (100)
Table II. Treatment characteristics. 
Variable N (%)
IMRT approach
Step-and-shoot 21 (49)
VMAT 22 (51)
PTV dose to tumor (Gy)
54 Gy/30 fractions 17 (40)
50.4 Gy/28 fractions 27 (60)
PTV dose to negative nodes (Gy)
45 Gy/30 fractions 28 (40)
42 Gy/28 fractions 11 (60)
Chemotherapy
None 3 (7)
5-FU 1 (2)
5-FU + MMC 39 (91)
5-FU + MMC cycles (39 pts)
1 4 (10)
2 35 (90)
Chemotherapy dose reduction (40 pts)
Yes 1 (3)
No 39 (97)
Biopsy-RT interval (days)
Mean 92
Range 30-193
RT duration (days)
Mean 42
Range 37-48
RT breaks ≥3 days
Yes 2 (5)
No 41 (95)
IMRT: Intensity-modulated radiotherapy; VMAT: volumetric modulated
arc therapy; PTV: planning target volume; 5-FU: 5-fluorouracil; MMC:
mytomicin C; RT: radiotherapy.
Table III. Acute toxicity.
Grade, N(%)
Acute toxicity 0 1 2 3 4
Skin 0 8 (18) 27 (64) 8 (18) 0
Gastrointestinal 1 (3) 13 (30) 29 (67) 0 0
Genitourinary 10 (23) 22 (51) 10 (23) 1 (3) 0
Genitalia 3 (7) 27 (63) 13 (30) 0 0
Anemia 26 (60) 14 (33) 3 (7) 0 0
Leukopenia 7 (15) 11 (26) 11 (26) 11 (26) 3 (7)
Neutropenia 14 (34) 10 (24) 7 (15) 7 (15) 5 (12)
Thrombocytopenia 25 (57) 10 (24) 3 (7) 4 (9) 1 (3)
clinical evidence on the role of CRT were unable to solve
this issue. The European Organisation for Research and
Treatment of Cancer trial was only targeted to locally
advanced disease and excluded patients with T1-T2 node-
negative disease from accrual (3). In the ACT I study, disease
in more than half of the patients was staged as T3-T4 and up
to 20% of enrolled cases had palpable nodal disease. Patients
with T1N0 stage disease were excluded (2). In the ACT II
trial, 46% of patients had T3-T4 tumors and 32% had
positive regional lymph nodes (16). Targeted analysis of
patients with early-stage disease has not been performed,
thus the benefit of concurrent chemotherapy in this setting
needs further investigation.
Some interesting data can be derived from robust and
retrospective analyses. Zilli et al. provided clinical data on a
cohort of 146 patients affected with early-stage node-
negative T1-T2 anal cancer (6). Results in terms of LRC and
CSS were similar to historical series. The outcome in the
cohort was excellent for patients with tumors of 3 cm or less,
with a 5-year LRC in excess of 85%, regardless of treatment
modality. Interestingly, patients treated with exclusive RT
had a lower 5-year LRC rate compared to those treated with
CRT (75.5% vs. 86.8%), even if the difference was not
statistically significant (p=0.065). This finding was also
confirmed after stratification according to different clinical-
and treatment-related factors (6). Another interesting study
was reported by De Bari et al. (7). Their retrospective
analysis on 122 patients with anal cancer found a benefit at
univariate analysis in terms of LRC (+9.8%; p=0.03), DFS
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Figure 1. Local control (A), and overall (B), cancer-specific (C) and disease-free (B) survival.
Figure 2. Colostomy-free survival. 
(+8.5%; p=0.04), CFS (+21.2%; p=0.001) and OS (+18.5%;
p=0.03) for the addition of chemotherapy. The advantage of
CRT was also confirmed by multivariate analysis (7). In this
series, the impact of chemotherapy was detected only for
those with T2 tumors.
Our patient cohort was treated according to RTOG 05-29
indications, employing IMRT and different daily doses to
different treatment sites following an SIB approach (11,17).
The RTOG 05-29 phase II trial was designed to investigate
whether dose-painted IMRT would reduce by at least 15%
the grade 2 or more GI and GU toxicity rates compared to
conventional radiation and concurrent 5-FU/MMC, as
delivered in the standard arm of the RTOG 98-11 trial, which
employed non-conformal techniques (namely anterior-
posterior parallel-opposed fields or 4-field conformal beam
arrangements) (11, 12). In that trial, the primary endpoint
was not reached, but the study showed a significant reduction
in acute G2 hematological (73% vs. 85% for RTOG 98-11),
G3 GI (21% vs. 36% for RTOG 98-11) and G3
dermatological acute adverse events (23% vs. 49% for RTOG
98-11) compared to standard RT (11). However, no results
in terms of local control and survival have been reported so
far. Our patients were treated similarly to RTOG 05-29.
Actuarial 3-year LRC, DFS, CSS and OS were 86.1% (95%
CI=69.6-94%), 75.5% (95% CI=56.4-87.1%), 93.8% (95%
CI=77.3-98.4%) and 90.8% (95% CI=74.1-96.9%). Actuarial
3-year CFS was 79.4% (95% CI=61.4-89.7%). These results
compare favorably with the available literature, especially
considering that our cohort included patients mainly with T2
tumors (88%) sized greater than 3 cm (50%). Five local
relapses were recorded, all salvaged with abdomino-perineal
resection according to Miles (18). All patients had T2 stage
and maximal tumor dimension ranging between 3 and 4 cm.
Notably, on multivariate analysis, tumor size in excess of 3
cm tended to predict poorer CFS (HR=8.6; 95% CI=84.7-
88.1%; p=0.069).
An advantage in delivering RT employing an SIB
approach is the contraction of the OTT. The 5-FU/MMC arm
of the RTOG 98-11 trial had a mean OTT of 49 days (12).
In the RTOG 05-29 trial, the mean OTT was 43 days,
comparably to our series (42 days) (11). The cohort reported
by Zilli et al. had a mean OTT of 62 days (6), while that
described by De Bari et al. was 52 days (7). As pointed out
by De Bari et al., concomitant chemotherapy may provide a
benefit in terms of clinical outcomes, especially when RT is
delivered optimally, with an acceptable toxicity profile able
to avoid treatment breaks and consequently shorten the
overall duration of CRT. Our results show that SIB-IMRT
delivered with concurrent chemotherapy similarly to the
RTOG 05-29 protocol has consistent clinical outcomes and
a mild toxicity profile. Treatment intensification for T2
tumors larger than 3 cm may be a hypothesis-generating
investigational field.
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